A cross-border pharmaceutical partnership creates interfaces: between product owner and manufacturer, regulatory holder and testing laboratory, global specification and local requirement, commercial schedule and quality decision. Most serious project failures begin when one of those interfaces is assumed rather than governed.

1. Quality responsibility cannot be outsourced

FDA’s guidance on contract manufacturing explains how parties can use quality agreements to define and document their manufacturing activities under CGMP. The commercial agreement allocates price, volume, intellectual property and liability; the quality agreement allocates the operational responsibilities required to keep the product and its records under control. Both are necessary, and neither replaces applicable law or regulatory responsibility. [1]

The practical implication is simple: “the other party handles quality” is never an adequate control. Each organization needs qualified oversight of the activities it owns and of the contracted activities it relies upon.

2. Build the system in four layers

Layer A — Governance and decision rights

Name the responsible quality units and establish who can approve specifications, master documents, suppliers, release documentation, deviations, changes, investigations and corrective and preventive actions. Define routine meeting frequency, urgent escalation channels, language of record and time limits for notification.

Layer B — Technical control strategy

Connect critical quality attributes, process parameters, material controls, analytical methods, sampling, validation, environmental or contamination controls where applicable, and continued monitoring. ICH Q10 provides a lifecycle model for a pharmaceutical quality system, while ICH Q9(R1) emphasizes a scientific, documented and proportionate approach to quality-risk decisions. [2] [3]

Layer C — Data and document integrity

Agree which system is authoritative for each record, how access is controlled, how contemporaneous entries and audit trails are reviewed, how raw data and metadata are retained, how translations are controlled and how documents are transferred. A PDF summary without access to the supporting record is not equivalent to governed evidence.

Layer D — Lifecycle and change governance

Control changes to process, equipment, methods, specifications, suppliers, materials, software, facility, packaging and labels. The workflow should evaluate product risk, validation needs, regulatory impact, market-specific implementation dates, inventory transition and notification obligations before execution.

3. Convert the quality agreement into an operating map

A useful quality agreement is specific enough that a new team member can answer “who does what, using which record, by when, and who approves the result?” Topics normally include:

  • technology transfer, qualification, validation and method transfer;
  • material and supplier qualification, sampling, testing and release;
  • batch documentation, review, disposition and certificates;
  • deviations, out-of-specification results, investigations and CAPA;
  • change control and regulatory-impact assessment;
  • complaints, quality defects, recalls and health-authority communications;
  • stability, retained samples, annual or periodic product review;
  • subcontracting, audits, inspection support and record retention;
  • business continuity, shortages and data-security incidents.

The agreement should be tested through tabletop scenarios before commercial execution. For example: a critical laboratory result is delayed on a public holiday; a supplier changes a manufacturing site; a market requests an urgent investigation; or an electronic system is unavailable. If the parties cannot identify the decision owner and evidence trail quickly, the agreement is not operational.

4. Resolve the predictable cross-border frictions

Language. Decide which documents require controlled translation and which language is authoritative. Informal translation is useful for discussion but should not silently become a GMP record.

Time zones and holidays. Define urgent-contact coverage and release-planning cutoffs. A small time difference can help operations, but only if responsibilities and availability are explicit.

Regulatory differences. Maintain a market matrix for specifications, test methods, labeling, stability, release and change requirements. A globally harmonized core does not eliminate country-specific commitments.

Data transfer. Use approved channels, least-privilege access and controlled exports. Sensitive technical information should move only under the agreed confidentiality and information-security controls.

Commercial pressure. Quality decisions must remain independent from shipment targets. Escalation can accelerate fact-finding; it cannot predetermine disposition.

5. Audit the system, not the presentation

Certificates and inspection history are useful context but do not establish product-specific readiness. Due diligence should sample actual workflows: recent deviations, CAPA effectiveness, change controls, training records, data review, maintenance, environmental monitoring where relevant, supplier oversight and management review. FDA describes CGMP as minimum requirements for methods, facilities and controls, and its quality-systems guidance encourages modern quality and risk-management approaches consistent with those requirements. [4] [5]

Readiness is also time-sensitive. An audit provides evidence for a defined scope and date; it is not a permanent guarantee. Ongoing performance metrics, event notification and periodic review are therefore part of the partnership design.

6. Measure leading indicators

Teams often monitor only release timeliness and rejected batches. A stronger review also tracks overdue investigations, repeat deviations, CAPA effectiveness, right-first-time documentation, method and equipment reliability, change-control cycle time, supplier events, stability signals, training effectiveness and notification timeliness. The purpose is not to create a larger dashboard; it is to identify weakening controls before they become supply or compliance failures.

Authoritative sources

  1. U.S. FDA — Contract Manufacturing Arrangements for Drugs: Quality Agreements
  2. ICH Q10 — Pharmaceutical Quality System
  3. ICH Q9(R1) — Quality Risk Management
  4. U.S. FDA — Current Good Manufacturing Practice (CGMP) Regulations
  5. U.S. FDA — Quality Systems Approach to Pharmaceutical CGMP Regulations
  6. WHO — Guidelines for pharmaceutical production and GMP

This article is an industry perspective for general business discussion. It is not legal, regulatory or medical advice. Project requirements must be confirmed with the responsible parties and applicable authorities.